Australia markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9800+0.0600 (+3.13%)
At close: 04:00PM EST
1.9900 +0.01 (+0.51%)
After hours: 07:49PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 501.47M
Enterprise value 252.02M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)41.97
Price/book (mrq)1.88
Enterprise value/revenue 22.96
Enterprise value/EBITDA -0.78

Trading information

Stock price history

Beta (5Y monthly) 1.01
52-week change 3-68.52%
S&P500 52-week change 3-11.22%
52-week high 36.7400
52-week low 31.3800
50-day moving average 31.9416
200-day moving average 32.3574

Share statistics

Avg vol (3-month) 35.86M
Avg vol (10-day) 35.37M
Shares outstanding 5249.49M
Implied shares outstanding 6N/A
Float 8245.59M
% held by insiders 11.53%
% held by institutions 147.82%
Shares short (14 Nov 2022) 446.15M
Short ratio (14 Nov 2022) 46.75
Short % of float (14 Nov 2022) 418.78%
Short % of shares outstanding (14 Nov 2022) 418.50%
Shares short (prior month 13 Oct 2022) 445.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 305 June 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-2,889.17%

Management effectiveness

Return on assets (ttm)-42.73%
Return on equity (ttm)-92.27%

Income statement

Revenue (ttm)10.98M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)3,038.20%
Gross profit (ttm)-247.47M
EBITDA -312.91M
Net income avi to common (ttm)-332.3M
Diluted EPS (ttm)-1.5420
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)281.88M
Total cash per share (mrq)1.13
Total debt (mrq)32.43M
Total debt/equity (mrq)12.16
Current ratio (mrq)3.69
Book value per share (mrq)1.07

Cash flow statement

Operating cash flow (ttm)-217.77M
Levered free cash flow (ttm)-97.63M